Methylene blue (MB) is one of the first-generation inhibitors disrupting tau aggregations and serving neuroprotective roles via promotion of mitochondrial antioxidants, which is now in phase II clinical trials for treating mild AD [183]. This evidence concerns the gene MAPT and Alzheimer disease.